)
Visual
earnings real time
CytoMed Therapeutics (GDTC) investor relations material
CytoMed Therapeutics H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary2 Oct, 2025
Executive summary
Revenue for the six months ended 30 June 2025 increased by 100% to SGD 156,000, driven by new private blood banking services in Malaysia and asset acquisition.
Net loss widened to SGD 2.25 million for the period, compared to SGD 1.09 million in the first half of 2024, due to higher research, share-based payments, and other expenses.
Adjusted net loss, excluding share-based payments, currency exchange losses, warrant liability fair value losses, and public company costs, was SGD 1.44 million.
Clinical-stage biopharma focused on allogeneic, off-the-shelf cell-based immunotherapies for cancer and degenerative diseases, with four product candidates in development and recent expansion into cord blood banking services.
Phase 1 trial for lead candidate CTM-N2D underway; asset acquisition in Malaysia enabled first revenue from private blood banking.
Financial highlights
Revenue for six months ended June 30, 2025 was SGD 155,887, primarily from private blood banking services.
Other operating income decreased by 8.5% year-over-year, mainly due to lower interest income.
Net loss widened to SGD 2.25 million, driven by higher research, share-based payments, and other expenses.
Cash and bank balances declined to SGD 2.86 million as of 30 June 2025, down from SGD 4.97 million at 31 December 2024.
Operating cash outflow increased to SGD 1.6 million from SGD 1.16 million year-over-year.
Outlook and guidance
Targeting completion of phase one trial for CTM-N2D in 2026.
Published preclinical study results in collaboration with MD Anderson Cancer Center in September 2025.
Applying for GDT trial in Malaysia and exploring international collaborations with income potential.
Signed ATM agreement to raise up to $4.3 million in August 2025.
Management expects current resources and proceeds from recent and potential equity offerings to be sufficient for at least the next 12 months.
How will ATM agreement impact cash runway?
Revenue growth outlook for LongevityBank?
Next steps for CTM-GDT clinical trials?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next CytoMed Therapeutics earnings date
H2 202527 Apr, 2026
Next CytoMed Therapeutics earnings date
H2 202527 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
CytoMed Therapeutics Limited is a biotechnology company focused on developing cell-based immunotherapies for cancer treatment. The company leverages advanced cellular technology to create novel therapeutic solutions that harness the immune system’s capabilities to target and eliminate cancer cells. CytoMed's research and development efforts concentrate on proprietary cell therapy platforms that aim to offer effective, potentially less toxic alternatives to conventional cancer treatments. CytoMed Therapeutics Limited is headquartered in Singapore, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage